Please login to the form below

Not currently logged in
Email:
Password:

Allergan acquires Vicept

Allergan has entered into an agreement to buy privately-owned Vicept Therapeutics

California-based pharmaceutical firm Allergan is set to acquire privately-owned Vicept Therapeutics for an undisclosed sum.

The agreement, which is expected to be finalised in the third quarter of 2011, includes a $75m cash upfront payment and up to $200m of milestone payments.

Dr Scott M Whitcup, executive vice president and chief scientific officer of Allergan, said: "The acquisition of Vicept Therapeutics will further enhance our dermatology research and development pipeline, and matches our corporate strategy and long-standing commitment to patients suffering from skin disorders."

Vicept Therapeutics' lead investigational product is V-101, a topical cream for the treatment of the erythema associated with rosacea, which has achieved positive results in two randomised, placebo-controlled phase II studies.

25th July 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
infill healthcare communication

infill is a dynamic and innovative, international healthcare agency with >25 years' experience in delivering healthcare communication, medical education and...

Latest intelligence

What pharma marketers can learn from behavioural science
Pharma behavioural science and traditional emotional marketing create a powerful mix of techniques that have impact on real lives....
NEW EU DATA PROTECTION REGULATION POISED TO CHANGE DATA PRIVACY LANDSCAPE
NEW EU DATA PROTECTION REGULATION POISED TO CHANGE DATA PRIVACY LANDSCAPE The bold digital clock featured on the EUGDPR (EU General Data Protection Regulation)1 website indicates – to the second...
Health knowledge: Why is it so important?
Health knowledge plays an important role in population health, but by itself is rarely enough to prompt a change in the behaviours that cause the risks....

Infographics